Argenx reports third quarter 2024 financial results and provides business update

$573 million in third quarter global net product sales cidp global expansion on track, with decisions on approval under review in japan, europe, china, and canada management to host conference call today at 1:30 pm cet (8:30 am et) regulated information - inside information october 31, 2024 7:00am cet amsterdam, the netherlands – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its third quarter 2024 financial results and provided a business update. “we delivered significant patient impact with vyvgart over the quarter, expanding our gmg footprint and delivering innovation to cidp patients three months into launch,” said tim van hauwermeiren, chief executive officer of argenx.
ARGX Ratings Summary
ARGX Quant Ranking